2020 / 02

DOI: 10.24075/brsmu.2020.014

ORIGINAL RESEARCH

Preventive pharmacotherapy of type 2 diabetes mellitus in patients with early carbohydrate metabolism disorders: long-term efficacy and clinical outcomes

Boeva VV1, Zavyalov AN2
About authors

1 Department of Endocrinology, Federal Clinical Centre of High Medical Technologies, Moscow Region, Novogorsk, Russia

2 Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Valentina V. Boeva
Ivanovskaya, 15A, Khimki, Moscow region, 141435; ur.xednay@VVaveob

About paper

Author contribution: Boeva VV planned the study; analyzed the literature; collected, analyzed and interpreted study results; wrote the manuscript; Zavyalov AN analyzed the literature; analyzed and interpreted study results; wrote the manuscript.

Received: 2020-01-09 Accepted: 2020-02-08 Published online: 2020-03-06
|
Fig. 1. A study plan. FPG — fasting plasma glucose test; OGTT — 75-gram oral glucose tolerance test
Fig. 2. Stratification of patients based on screening data for further T2DM diagnostic tests. FPG — fasting plasma glucose test; MS — metabolic syndrome; OGTT — 75-gram oral glucose tolerance test; RF — risk factors for T2DM
Fig. 3. Stratification of patients by the initial state of carbohydrate metabolism and prescribed therapy. M+A – therapy with metformin and acarbose
Fig. 4. Stratification of patients with IGT/IFG 10 years after the end of the active follow-up phase
Fig. 5. Distribution of patients by type and duration of preventive pharmacotherapy after the end of the active follow-up phase (years 1 through 10)
Table 1. Long-term outcomes in patients who had and had not been receiving preventive pharmacotherapy
Note: SI — statistically insignificant.
Table 2. Long-term results of OGTT in patients with different disorders of carbohydrate metabolism undergoing long-term preventive pharmacotherapy
Table 3. Long-term results of OGTT in patients with different disorders of carbohydrate metabolism who did not have long-term preventive pharmacotherapy